AtaiBeckley's BPL-003 Cleared for Phase 3 in Treatment-Resistant Depression After Successful FDA Meeting
ATAI has more than doubled off its 52-week low of $1.15.
Summary
AtaiBeckley announced a successful End-of-Phase 2 (EOP2) meeting with the FDA for BPL-003, its proprietary intranasal formulation of mebufotenin benzoate, for treatment-resistant depression (TRD). The FDA indicated support for the proposed pivotal program, allowing BPL-003 to advance into Phase 3 studies. This is a highly material and positive development for the clinical-stage biotechnology company, as it significantly de-risks the program by confirming regulatory alignment on the development path for a key pipeline asset. The company outlined plans for two parallel Phase 3 studies, ReConnection 1 and ReConnection 2, designed to evaluate single and two-dose induction models. Investors will now closely monitor the initiation and progress of these pivotal trials, which are critical for the company's long-term valuation. AtaiBeckley will host a Virtual Investor Day on March 6, 2026, to provide further details on the Phase 3 clinical strategy.
At the time of this announcement, ATAI was trading at $3.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $1.15 to $6.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.